Dr Reddys Laboratories (RDY) Total Current Liabilities (2009 - 2026)

Dr Reddys Laboratories (RDY) has reported Total Current Liabilities for 10 consecutive years, with $1.8 billion the latest figure, recorded in Q1 2026.

• Quarterly Total Current Liabilities rose 17.03% year-over-year to $1.8 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 billion (up 17.03% YoY) and the FY2026 annual result came in at $1.8 billion, up 17.03% from the prior year.
• Total Current Liabilities grew to $1.8 billion in Q1 2026 per RDY's latest filing, from $1.5 billion in the prior quarter.
• Over the last five years, Total Current Liabilities for RDY reached as high as $1.8 billion in Q1 2026 and fell as low as $1.0 billion in Q1 2023.
• A 5-year average of $1.3 billion and a median of $1.2 billion in 2022 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2023 — Total Current Liabilities slipped 15.74% — and 2025, when it jumped 32.55%.
• Year by year, Total Current Liabilities stood at $1.2 billion in 2022, then dropped by 15.74% to $1.0 billion in 2023, then advanced by 10.34% to $1.2 billion in 2024, then soared by 32.55% to $1.5 billion in 2025, then rose by 17.03% to $1.8 billion in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $1.8 billion, $1.5 billion, and $1.2 billion for Q1 2026, Q1 2025, and Q1 2024 respectively.